Definitive Contract 75N93026C00009
Award Date 7/1/26
Potential Completion Date 6/30/29
Potential Value $4.5M
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Atlanta, GA 30318, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded a $4.477 million definitive contract to Asell, LLC for development of radiation and nuclear medical countermeasures and biodosimetry devices on July 1, 2026. The originating solicitation calls for advanced development and validation of the CellRadx qualitative biodosimetry triage test, with performance running from July 1, 2026 through June 30, 2027 under a base period, and extending to an ultimate completion date of June 30,...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on August 25, 2015, exercising Option 4 Year 5 (Period 9/1/2019–8/31/2020) for $1,999,679 in administrative and technical support for radiation/nuclear medical countermeasure product development activities under a cost-plus-fixed-fee structure. The order supports all other task orders under the base contract through administrative and technical activities. Place of performance is Menlo Park,...
- This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical...
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on September 29, 2017, with a ceiling value of $15.56 million for radiation/nuclear medical countermeasure product development support services.</p> <p>Place of performance is Menlo Park, California. The order is priced as cost-plus-fixed-fee with an ultimate completion date of December 15, 2020. No set-aside was used.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,624,116.99 definitive contract to the University of Wisconsin System to provide centralized dosimetry guidance and monitoring of radiation sources and irradiation protocols across institutions funded by NIAID's Radiation Nuclear Countermeasures Program (RNCP) portfolio. The contract, which has no set-aside designation, was awarded on June 1, 2020 and runs through May 31, 2025. The contractor will be responsible for...
- The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on September 22, 2016, with a ceiling value of $7.9 million for radiation and nuclear medical countermeasure product development support services under a cost-plus-fixed-fee pricing structure. The delivery order, Task Order B-2, covers animal model development and initial efficacy testing of candidate medical countermeasures, with performance at Sri International's Menlo Park, California...
- <p>The National Institute of Allergy and Infectious Diseases issued a delivery order to Sri International on February 6, 2017, with a ceiling value of $575,362.67 for radiation/nuclear medical countermeasure product development support services.</p> <p>Place of performance is Menlo Park, CA. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of February 5, 2020. No set-aside was used for this delivery order.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The...
- Ceramedix Holding, LLC was awarded a $4.22M cost-plus-fixed-fee definitive contract by the National Institute of Allergy and Infectious Diseases on July 1, 2023, to develop anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract, with performance completing June 30, 2027, supports the NIH's broader mission to develop safe and effective countermeasures that reduce radiation-associated mortality and morbidity in mass casualty incidents....